CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Protagonist Therapeutics, Inc. - PTGX CFD

    17.70
    1.26%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.12
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Protagonist Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 17.45
    Open* 17.5
    1-Year Change* 110.84%
    Day's Range* 17.5 - 17.67
    52 wk Range 7.24-30.10
    Average Volume (10 days) 470.67K
    Average Volume (3 months) 20.77M
    Market Cap 1.08B
    P/E Ratio -100.00K
    Shares Outstanding 57.53M
    Revenue N/A
    EPS -2.67
    Dividend (Yield %) N/A
    Beta 1.86
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 26, 2023 17.45 0.29 1.69% 17.16 18.14 17.16
    Sep 25, 2023 17.17 0.38 2.26% 16.79 17.17 16.37
    Sep 22, 2023 17.08 0.53 3.20% 16.55 17.12 16.52
    Sep 21, 2023 16.92 0.16 0.95% 16.76 17.01 16.49
    Sep 20, 2023 16.97 -0.43 -2.47% 17.40 17.75 16.92
    Sep 19, 2023 17.63 0.15 0.86% 17.48 17.87 17.42
    Sep 18, 2023 17.60 -0.11 -0.62% 17.71 17.97 17.54
    Sep 15, 2023 17.85 -0.12 -0.67% 17.97 18.03 17.32
    Sep 14, 2023 17.95 -0.27 -1.48% 18.22 18.59 17.82
    Sep 13, 2023 18.41 -0.06 -0.32% 18.47 18.84 18.39
    Sep 12, 2023 18.78 0.05 0.27% 18.73 19.11 18.63
    Sep 11, 2023 18.83 -0.12 -0.63% 18.95 18.99 18.58
    Sep 8, 2023 19.00 0.53 2.87% 18.47 19.07 18.47
    Sep 7, 2023 18.70 -0.82 -4.20% 19.52 19.53 18.69
    Sep 6, 2023 19.75 0.39 2.01% 19.36 19.79 19.10
    Sep 5, 2023 19.54 0.03 0.15% 19.51 19.85 19.12
    Sep 1, 2023 19.49 -0.34 -1.71% 19.83 20.18 19.41
    Aug 31, 2023 19.78 0.30 1.54% 19.48 20.26 19.48
    Aug 30, 2023 19.89 -0.09 -0.45% 19.98 20.26 19.58
    Aug 29, 2023 20.20 0.23 1.15% 19.97 20.43 19.97

    Protagonist Therapeutics, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Protagonist Therapeutics Inc Earnings Release
    Q3 2023 Protagonist Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 26.581 27.357 28.628 0.231 30.925
    Total Operating Expense 157.954 153.202 93.729 80.752 73.194
    Selling/General/Admin. Expenses, Total 31.739 27.196 18.638 15.749 13.697
    Research & Development 126.215 126.006 74.506 65.003 59.497
    Operating Income -131.373 -125.845 -65.101 -80.521 -42.269
    Interest Income (Expense), Net Non-Operating 4.06 0.443 0.302 2.644 2.546
    Other, Net -0.08 -0.149 -0.046 -0.001 0
    Net Income Before Taxes -127.393 -125.551 -64.845 -77.878 -39.723
    Net Income After Taxes -127.393 -125.551 -66.15 -77.187 -38.924
    Net Income Before Extra. Items -127.393 -125.551 -66.15 -77.187 -38.924
    Net Income -127.393 -125.551 -66.15 -77.187 -38.924
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -127.393 -125.551 -66.15 -77.187 -38.924
    Income Available to Common Incl. Extra. Items -127.393 -125.551 -66.15 -77.187 -38.924
    Diluted Net Income -127.393 -125.551 -66.15 -77.187 -38.924
    Diluted Weighted Average Shares 49.0422 46.3229 34.3965 25.894 22.3645
    Diluted EPS Excluding Extraordinary Items -2.59762 -2.71034 -1.92316 -2.98088 -1.74044
    Diluted Normalized EPS -2.59762 -2.71034 -1.91211 -2.98088 -1.74044
    Revenue 26.581 27.357 28.628 0.231 30.925
    Total Extraordinary Items
    Dividends per Share - Common Stock Primary Issue 0
    Unusual Expense (Income) 0 0 0.585
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0.859
    Revenue 0 0 0 0 0.859
    Total Operating Expense 42.354 36.021 36.516 32.303 42.302
    Selling/General/Admin. Expenses, Total 9.172 8.605 6.632 6.901 7.691
    Research & Development 33.182 27.416 29.884 25.402 34.611
    Operating Income -42.354 -36.021 -36.516 -32.303 -41.443
    Interest Income (Expense), Net Non-Operating 3.913 2.491 2.251 1.157 0.484
    Other, Net -0.019 -0.195 0.071 -0.086 -0.078
    Net Income Before Taxes -38.46 -33.725 -34.194 -31.232 -41.037
    Net Income After Taxes -38.46 -33.725 -34.194 -31.232 -41.037
    Net Income Before Extra. Items -38.46 -33.725 -34.194 -31.232 -41.037
    Net Income -38.46 -33.725 -34.194 -31.232 -41.037
    Income Available to Common Excl. Extra. Items -38.46 -33.725 -34.194 -31.232 -41.037
    Income Available to Common Incl. Extra. Items -38.46 -33.725 -34.194 -31.232 -41.037
    Diluted Net Income -38.46 -33.725 -34.194 -31.232 -41.037
    Diluted Weighted Average Shares 56.7757 50.5737 49.2549 49.1076 49.0499
    Diluted EPS Excluding Extraordinary Items -0.6774 -0.66685 -0.69422 -0.63599 -0.83664
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.6774 -0.66685 -0.69422 -0.63599 -0.83664
    Unusual Expense (Income) 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 243.077 340.736 315.606 145.311 137.503
    Cash and Short Term Investments 237.355 326.9 305.809 133.017 128.853
    Cash & Equivalents 125.744 123.665 117.358 33.006 82.233
    Short Term Investments 111.611 203.235 188.451 100.011 46.62
    Total Receivables, Net 0.052 5.333 3.821 7.499 6.511
    Prepaid Expenses 5.67 8.503 5.966 4.785 2.129
    Other Current Assets, Total 0.01 0.01 0.01
    Total Assets 247.928 347.695 324.468 154.917 139.472
    Property/Plant/Equipment, Total - Net 4.626 6.734 6.412 7.723 0.861
    Property/Plant/Equipment, Total - Gross 9.88 10.992 9.885 10.364 2.938
    Accumulated Depreciation, Total -5.254 -4.258 -3.473 -2.641 -2.077
    Long Term Investments 2
    Other Long Term Assets, Total 0.225 0.225 0.45 1.883 1.108
    Total Current Liabilities 31.179 44.016 40.241 35.406 26.158
    Accounts Payable 3.64 1.6 3.075 2.79 5.711
    Payable/Accrued
    Accrued Expenses 27.055 39.509 19.875 13.494 11.068
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 32.32 47.674 44.862 74.953 26.957
    Total Long Term Debt 0 0 0 9.794 0
    Long Term Debt 0 9.794
    Total Equity 215.608 300.021 279.606 79.964 112.515
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.00049 0.00048 0.00044 0.00027 0
    Additional Paid-In Capital 752.722 709.682 563.389 297.846 253.222
    Retained Earnings (Accumulated Deficit) -536.755 -409.362 -283.811 -217.661 -140.474
    Other Equity, Total -0.35949 -0.29948 0.02756 -0.22127 -0.233
    Total Liabilities & Shareholders’ Equity 247.928 347.695 324.468 154.917 139.472
    Total Common Shares Outstanding 49.3392 47.8383 43.7455 27.2176 23.1872
    Other Current Liabilities, Total 0.484 2.907 17.291 19.122 9.379
    Other Liabilities, Total 1.141 3.658 4.621 29.753 0.799
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 235.736 243.077 276.617 304.302 341.522
    Cash and Short Term Investments 230.759 237.355 267.437 291.89 305.289
    Cash & Equivalents 127.686 125.744 152.816 120.237 98.477
    Short Term Investments 103.073 111.611 114.621 171.653 206.812
    Total Receivables, Net 0.051 0.052 0.62 3.363 28.504
    Prepaid Expenses 4.926 5.67 8.56 9.049 7.729
    Total Assets 239.858 247.928 282.174 310.512 348.296
    Property/Plant/Equipment, Total - Net 3.897 4.626 5.332 5.985 6.549
    Long Term Investments
    Other Long Term Assets, Total 0.225 0.225 0.225 0.225 0.225
    Total Current Liabilities 23.229 31.179 36.754 40.088 43.456
    Accounts Payable 4.021 3.64 4.715 1.412 7.159
    Accrued Expenses 18.852 27.055 31.816 38.336 34.995
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.356 0.484 0.223 0.34 1.302
    Total Liabilities 23.691 32.32 38.558 42.534 46.518
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.462 1.141 1.804 2.446 3.062
    Total Equity 216.167 215.608 243.616 267.978 301.778
    Common Stock 0.001 0.00049 0.00049 0.00049 0.00049
    Additional Paid-In Capital 786.768 752.722 746.657 740.027 732.542
    Retained Earnings (Accumulated Deficit) -570.48 -536.755 -502.561 -471.329 -430.292
    Other Equity, Total -0.122 -0.35949 -0.48049 -0.72049 -0.47249
    Total Liabilities & Shareholders’ Equity 239.858 247.928 282.174 310.512 348.296
    Total Common Shares Outstanding 51.4405 49.3392 49.1984 48.6839 48.5521
    Other Current Assets, Total
    Redeemable Preferred Stock 0 0 0 0 0
    Property/Plant/Equipment, Total - Gross 9.389 9.88 10.302 10.721 11.074
    Accumulated Depreciation, Total -5.492 -5.254 -4.97 -4.736 -4.525
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -127.393 -125.551 -66.15 -77.187 -38.924
    Cash From Operating Activities -108.137 -107.865 -72.484 -41.527 -49.947
    Cash From Operating Activities 1.034 0.813 0.789 0.703 0.527
    Non-Cash Items 25.988 20.187 10.455 9.588 7.125
    Changes in Working Capital -7.766 -3.314 -19.016 26.144 -18.017
    Cash From Investing Activities 91.468 -15.86 -90.965 -53.71 2.213
    Capital Expenditures -0.795 -1.101 -0.471 -0.967 -0.486
    Other Investing Cash Flow Items, Total 92.263 -14.759 -90.494 -52.743 2.699
    Cash From Financing Activities 18.838 129.923 247.626 46.036 24.115
    Issuance (Retirement) of Stock, Net 19.001 130.112 258.164 36.271 24.115
    Foreign Exchange Effects -0.09 -0.126 0.175 -0.026 -0.177
    Net Change in Cash 2.079 6.072 84.352 -49.227 -23.796
    Deferred Taxes 0 1.438 -0.775 -0.658
    Cash Taxes Paid 0 0 0.438 0.07
    Issuance (Retirement) of Debt, Net 0 -10.524 9.765
    Financing Cash Flow Items -0.163 -0.189 -0.014
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -33.725 -127.393 -93.199 -61.967 -20.93
    Cash From Operating Activities -34.347 -108.137 -76.502 -51.301 -37.666
    Cash From Operating Activities 0.248 1.034 0.778 0.508 0.249
    Non-Cash Items 7.107 25.988 20.806 14.362 6.877
    Changes in Working Capital -7.977 -7.766 -4.887 -4.204 -23.862
    Cash From Investing Activities 9.826 91.468 87.533 30.258 -4.476
    Capital Expenditures -0.01 -0.795 -0.725 -0.563 -0.273
    Other Investing Cash Flow Items, Total 9.836 92.263 88.258 30.821 -4.203
    Cash From Financing Activities 26.463 18.838 18.285 17.605 16.925
    Financing Cash Flow Items -0.1 -0.163 -0.163 -0.161 -0.186
    Issuance (Retirement) of Stock, Net 26.563 19.001 18.448 17.766 17.111
    Foreign Exchange Effects 0 -0.09 -0.165 0.01 0.029
    Net Change in Cash 1.942 2.079 29.151 -3.428 -25.188
    Deferred Taxes 0
    Issuance (Retirement) of Debt, Net 0
    Cash Taxes Paid 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Protagonist Therapeutics, Inc. Company profile

    About Protagonist Therapeutics Inc

    Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Protagonist Therapeutics Inc revenues decreased 4% to $27.4M. Net loss increased 90% to $125.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 66% to $117M (expense), General and administrative - Balancin increase of 33% to $19.8M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    7707 Gateway Blvd Ste 140
    NEWARK
    CALIFORNIA 94560-1160
    US

    Income Statement

    • Annual
    • Quarterly

    News

    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    People also watch

    XRP/USD

    0.51 Price
    +0.770% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    91.63 Price
    +1.550% 1D Chg, %
    Long position overnight fee 0.0436%
    Short position overnight fee -0.0655%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    US100

    14,607.30 Price
    +0.340% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    BTC/USD

    26,828.00 Price
    +2.370% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading